Literature DB >> 9761404

Depressive disorders among somatizing patients in primary health care.

M Posse1, T Hällström.   

Abstract

Unrecognized, untreated and undertreated depressive disorders incur inordinate human and economic costs, despite the availability of an exclusive array of clinical interventions. The aim of this study was to identify cases of masked depression in primary health care, employing a two-stage design. In the first stage, involving a study of 442 patients, the prevalence of recognized depression was 1.8%. In the second step, 62 patients from stage 1 were investigated further because of their high score on somatization tendency. In total, 41 of the 62 patients were found to have a mood disorder according to DSM-III-R, i.e. a major depressive disorder or dysthymia. Two patients were found to have already had a diagnosis of major depression assigned to them in stage 1, but they were joined by 13 more patients. A further 26 patients were found to be suffering from dysthymia, nine had adjustment disorders with depressed mood, and 12 patients showed no signs of depressed mood. For the group suffering from a current episode of major depression or dysthymia, the prevalence rate increased to 11.7% in the initial total population after stage 2. The diagnostic category with the highest rate of depressed patients was 'musculoskeletal diseases'. Patients with masked depression had higher scores for alexithymia and psychasthenia than depressed patients who were directly diagnosed.

Entities:  

Mesh:

Year:  1998        PMID: 9761404     DOI: 10.1111/j.1600-0447.1998.tb10065.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  9 in total

1.  Alexithymia and Self-Esteem in Patients with Ankylosing Spondylitis.

Authors:  Mustafa Solmaz; Zerrin Binbay; Muharrem Cidem; Selim Sağir; İlhan Karacan
Journal:  Noro Psikiyatr Ars       Date:  2014-12-01       Impact factor: 1.339

2.  Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression.

Authors:  Craig H. Mallinckrodt; David J. Goldstein; Michael J. Detke; Yili Lu; John G. Watkin; Pierre V. Tran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

3.  The level of recognition of physical symptoms in patients with a major depression episode in the outpatient psychiatric practice in Puerto Rico: an observational study.

Authors:  Jorge M Tamayo; Karis Román; Juan J Fumero; María Rivas
Journal:  BMC Psychiatry       Date:  2005-06-20       Impact factor: 3.630

4.  Education of the primary health care staff based on acceptance and commitment therapy is associated with reduced sick leave in a prospective controlled trial.

Authors:  Åsa Kadowaki; Anna-Karin Alvunger; Hanna Israelsson Larsen; Anna Persdotter; Marta Stelmach Zak; Peter Johansson; Fredrik H Nystrom
Journal:  BMC Fam Pract       Date:  2021-09-08       Impact factor: 2.497

5.  Alexithymia in ankylosing spondylitis.

Authors:  Deniz Karabıçak; Bilinç Doğruöz Karatekin; Afitap İçağasıoğlu
Journal:  Turk J Phys Med Rehabil       Date:  2021-09-01

Review 6.  Beyond somatisation: a review of the understanding and treatment of medically unexplained physical symptoms (MUPS).

Authors:  Christopher Burton
Journal:  Br J Gen Pract       Date:  2003-03       Impact factor: 5.386

7.  Effect of five-consecutive-day exposure to an anxiogenic stressor on sleep-wake activity in rats.

Authors:  Matthew W O'Malley; Rachel Lea Fishman; Domenic A Ciraulo; Subimal Datta
Journal:  Front Neurol       Date:  2013-02-26       Impact factor: 4.003

8.  IPS multicentric study: Functional somatic symptoms in depression.

Authors:  Sandeep Grover; Ajit Avasthi; Kamal Kalita; P K Dalal; G P Rao; R K Chadda; Bhavesh Lakdawala; Govind Bang; Kaustav Chakraborty; Sudhir Kumar; P K Singh; Puneet Kathuria; M Thirunavukarasu; P S V N Sharma; T Harish; Nilesh Shah; Kamla Deka
Journal:  Indian J Psychiatry       Date:  2013-01       Impact factor: 1.759

9.  Duloxetine in the treatment of major depressive disorder.

Authors:  David J Goldstein
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.